NCT03288636 is a Phase 1 clinical trial of Danoprevir in HCV, sponsored by Ascletis Pharmaceuticals Co., Ltd..

Who is sponsoring NCT03288636?

NCT03288636 is sponsored by Ascletis Pharmaceuticals Co., Ltd..

What drugs are being tested in NCT03288636?

Interventions in NCT03288636: Danoprevir, Ritonavir, Ravidasvir, Placebo.

Is NCT03288636 still recruiting?

NCT03288636 is currently completed. Last updated 17 January 2018.

Last reviewed 2018-01-17 · How we verify

NCT03288636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Completed Phase 1 Last updated 17 January 2018

What this trial tests

Phase 1 trial testing Danoprevir in HCV in 18 participants. Completed in 28 October 2017.

Timeline

8 August 2017

Primary endpoint
14 September 2017

28 October 2017

Quick facts

Lead sponsor	Ascletis Pharmaceuticals Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	18
Start date	8 August 2017
Primary completion	14 September 2017
Estimated completion	28 October 2017
Sites	1 location across China

Drugs / interventions tested

Danoprevir — full drug profile →
Ritonavir (ritonavir) — full drug profile →
Ravidasvir — full drug profile →
Placebo

Conditions studied

HCV — all drugs for HCV →

Sponsor

Ascletis Pharmaceuticals Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with HCV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the Pharmacokinetics and Safety of single dose of Ravidasvir and Danoprevir/r and repeated doses of Ravidasvir in combination with Danoprevir/r in healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.
Meshram RJ, Kathwate GH, Gacche RN. · · 2022 · cited 9× · PMID 35089390 · DOI 10.1007/s00705-022-05375-0
Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.
Wu G, Zhou H, Wu J, Lv D, et al · · 2021 · cited 2× · PMID 34252301 · DOI 10.1128/aac.00600-21

Verify or expand the search:

Other trials of Danoprevir

Trials testing the same drug.

NCT03362814 — Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, · Phase 2, PHASE3 · completed
NCT03020134 — Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China · Phase 1 · completed

Other recruiting trials for HCV

Currently open trials in the same condition.

NCT07095192 — Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada · recruiting
NCT06316739 — The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City · NA · active not recruiting
NCT05794646 — Community Intervention to Eliminate HCV Among People Who Use Drugs. · NA · active not recruiting
NCT06528626 — Tools to Identify People At Risk or Already Infected with HIV and HCV · NA · recruiting
NCT05781568 — Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) · recruiting

Other Ascletis Pharmaceuticals Co., Ltd. trials

Trials by the same sponsor.

NCT06248008 — A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris · Phase 3 · completed
NCT06192264 — A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to · Phase 3 · completed
NCT05718518 — Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects · Phase 1 · completed
NCT05596045 — Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients · Phase 1 · withdrawn
NCT05523141 — Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ascletis Pharmaceuticals Co., Ltd.
Last refreshed: 17 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing